
Stocks pulled back on Friday, with the Nasdaq dropping over 3% to wipe out its year-to-date gains and the Dow entering correction territory, down more than 10% from its closing
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| RVMD | Revolution Medicines | 161.20 | 89.54 | 124.96% |
| Name | Price | % Change | |
|---|---|---|---|
| $161.20 | +124.96% |

Stocks pulled back on Friday, with the Nasdaq dropping over 3% to wipe out its year-to-date gains and the Dow entering correction territory, down more than 10% from its closing

The company states: “Revolution Medicines (RVMD) announced encouraging updated results from the Phase 1/2 RMC-GI-102 open-label study evaluating RASONQUE, or daraxonrasib, in combination with gemcitabine and nab-paclitaxel as a potential

Leerink initiated coverage of Erasca (ERAS) with an Outperform rating and $35 price target. Erasca’s ERAS-0015 has an elegantly enhance exposure profile, potentially enabling the efficacy without the same level

Revolution Medicines (RVMD) announced that the European Commission has approved RASONQUE for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

Revolution Medicines, Inc. (($RVMD)) has held its Q3 earnings call. Read on for the main highlights of the call. Revolution Medicines delivered a strongly positive earnings call, led by FDA

Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Revolution Medicines (RVMD) to $247 from $272 and keeps an Overweight rating on the shares. The firm adjusted estimates

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $350 from $280 and keeps a Buy rating on the shares. The firm says Rasonque

Morgan Stanley raised the firm’s price target on Revolution Medicines (RVMD) to $272 from $255 and keeps an Overweight rating on the shares. Rasonque’s first commercial quarter came in well

RBC Capital raised the firm’s price target on Revolution Medicines (RVMD) to $321 from $260 and keeps an Outperform rating on the shares. The Rasonque launch far exceeded RBC’s expectations,

TD Cowen raised the firm’s price target on Revolution Medicines (RVMD) to $270 from $250 and keeps a Buy rating on the shares. Rasonque’s $198MM sales from 5 weeks in
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 20, 2026 | ||||
| hold | Reiterated | Nov 20, 2026 | ||||
| buy | Reiterated | Nov 17, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Assigned | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 1, 2027TBA | $34.48B | $-1.15 | $403.95M | -0.20 | -17.42 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.